Hepatic failure and hepatorenal syndrome secondary to erlotinib. Safety reminder.
Saif
Muhammad Wasif
MW
D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004348:Drug Labeling / Q000592:standards; D064420:Drug-Related Side Effects and Adverse Reactions; D000069347:Erlotinib Hydrochloride; D006530:Hepatorenal Syndrome / Q000139:chemically induced*; D006801:Humans; D017093:Liver Failure / Q000139:chemically induced*; D011358:Product Surveillance, Postmarketing; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000493:pharmacokinetics; D011799:Quinazolines / Q000009:adverse effects* / Q000493:pharmacokinetics
D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride